Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2014 01:59 ET | Source: H. Lundbeck A/S

Solid growth of New Products, positive pipeline development and financial outlook maintained

Valby, Copenhagen, 2014-11-05 07:59 CET (GLOBE NEWSWIRE) -- HIGHLIGHTS New Products up 46% in local currency and 40% reported in the first nine months of the year US revenue was...
November 03, 2014 11:17 ET | Source: H. Lundbeck A/S

Aripiprazol til én gang månedlig dosering giver væsentligt forbedret livskvalitet målt på QLS skalaen sammenlignet med paliperidon palmitat hos patienter med skizofreni

QUALIFY-studiet sammenlignede effekten af aripiprazol til én gang månedlig dosering med paliperidon til én gang måned dosering hos voksne patienter med skizofreni Patienter behandlet...
November 03, 2014 11:17 ET | Source: H. Lundbeck A/S

Aripiprazole once-monthly shows superior effectiveness to paliperidone palmitate once-monthly on quality of life scale in patients with schizophrenia

The head-to-head QUALIFY study compared the effectiveness of aripiprazole once-monthly to paliperidone palmitate once-monthly in adult patients with schizophrenia Patients treated with...
October 25, 2014 05:30 ET | Source: H. Lundbeck A/S

Lundbeck præsenterer nye effekt- og tolerabilitetsanalyser for desmoteplase hos patienter med akut iskæmisk slagtilfælde

Valby, København, 2014-10-25 11:30 CEST (GLOBE NEWSWIRE) -- Ved analyse af de patienter, der opfyldte alle protokolkrav (per-protokol population) i DIAS-3 viste desmoteplase en forbedring i...
October 25, 2014 05:30 ET | Source: H. Lundbeck A/S

Lundbeck presents new efficacy and safety data analyses for desmoteplase in patients with acute ischaemic stroke

Valby, Copenhagen, 2014-10-25 11:30 CEST (GLOBE NEWSWIRE) -- In the per-protocol population desmoteplase was associated with better functional outcome compared to placebo as assessed by the...
September 24, 2014 02:01 ET | Source: H. Lundbeck A/S

US FDA accepts Otsuka and Lundbeck's filing for review of brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

Valby, Copenhagen, 2014-09-24 08:01 CEST (GLOBE NEWSWIRE) -- In the clinical program, brexpiprazole demonstrated improvement in symptoms in both schizophrenia and as adjunctive therapy...
September 24, 2014 02:01 ET | Source: H. Lundbeck A/S

De amerikanske sundhedsmyndigheder (FDA) har accepteret Otsuka og Lundbecks registreringsansøgning for brexpiprazol til behandling af skizofreni og til kombinationsbehandling af svær depression

Valby, København, 2014-09-24 08:01 CEST (GLOBE NEWSWIRE) -- I det kliniske program viste brexpiprazol bedring af symptomer på både skizofreni samt som kombinationsbehandling af svær...
September 16, 2014 02:00 ET | Source: H. Lundbeck A/S

European launch of Brintellix commences in Denmark

Valby, 2014-09-16 08:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) has now started the launch of its novel antidepressant Brintellix (vortioxetine) in Denmark. This marks the first European...
September 16, 2014 02:00 ET | Source: H. Lundbeck A/S

Europæisk lancering af Brintellix starter i Danmark

Valby, 2014-09-16 08:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) har nu indledt lanceringen af dets nye antidepressivum Brintellix (vortioxetine) i Danmark. Det markerer starten på...
September 02, 2014 10:00 ET | Source: H. Lundbeck A/S

Lundbeck announces availability of NORTHERA™ in the U.S.

Valby, 2014-09-02 16:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) announced today that NORTHERA™ (droxidopa) capsules for oral use are now available through its U.S. subsidiary Lundbeck...